GSK3B and esophageal squamous cell carcinoma: Treatment with the GSK3β inhibitors (AR-A014418, SB-216763) reduced viability of all ESCC cells in a dose- and time-dependent manner, while sparing normal TYNEK-3 cells (Fig. 2A, Supplementary Information, Fig. S4A).